tradingkey.logo

tradingkey.logo
怜玢


AbbVie Inc

ABBV
りォッチリストに远加
256.460USD
-3.750-1.44%
終倀 09-04 16:00ET
452.92B時䟡総額
126.14盎近12ヶ月PER

詳现情報 AbbVie Inc 䌁業名

AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).

AbbVie Inc プロフィヌル


䌁業コヌドABBV
䌚瀟名AbbVie Inc
䞊堎日Jan 02, 2013
最高経営責任者「CEO」Michael (Robert A)
埓業員数55000
蚌刞皮類Ordinary Share
決算期末Jan 02
本瀟所圚地1 N Waukegan Rd
郜垂NORTH CHICAGO
蚌刞取匕所NASDAQ OMX NASDAQ Basic NYSE
囜United States of America
郵䟿番号60064
電話番号18479327900
りェブサむトhttps://www.abbvie.com/
䌁業コヌドABBV
䞊堎日Jan 02, 2013
最高経営責任者「CEO」Michael (Robert A)

AbbVie Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Azita Saleki-Gerhardt, Ph.D.
Dr. Azita Saleki-Gerhardt, Ph.D.
Executive Vice President, Chief Operations Officer
Executive Vice President, Chief Operations Officer
204.37K
+0.05%
Dr. Azita Saleki-Gerhardt, Ph.D.
Dr. Azita Saleki-Gerhardt, Ph.D.
Executive Vice President, Chief Operations Officer
Executive Vice President, Chief Operations Officer
204.37K
+0.05%
Dr. Azita Saleki-Gerhardt, Ph.D.
Dr. Azita Saleki-Gerhardt, Ph.D.
Executive Vice President, Chief Operations Officer
Executive Vice President, Chief Operations Officer
204.37K
+0.05%
Mr. Thomas C. (Tom) Freyman, CPA
Mr. Thomas C. (Tom) Freyman, CPA
Independent Director
Independent Director
135.75K
+0.82%
Mr. Thomas C. (Tom) Freyman, CPA
Mr. Thomas C. (Tom) Freyman, CPA
Independent Director
Independent Director
135.75K
+0.82%
Mr. Thomas C. (Tom) Freyman, CPA
Mr. Thomas C. (Tom) Freyman, CPA
Independent Director
Independent Director
135.75K
+0.82%
Dr. Roopal Thakkar, M.D.
Dr. Roopal Thakkar, M.D.
Executive Vice President - Research & Development, Chief Scientific Officer
Executive Vice President - Research & Development, Chief Scientific Officer
55.37K
+5.41%
Dr. Roopal Thakkar, M.D.
Dr. Roopal Thakkar, M.D.
Executive Vice President - Research & Development, Chief Scientific Officer
Executive Vice President - Research & Development, Chief Scientific Officer
55.37K
+5.41%
Dr. Roopal Thakkar, M.D.
Dr. Roopal Thakkar, M.D.
Executive Vice President - Research & Development, Chief Scientific Officer
Executive Vice President - Research & Development, Chief Scientific Officer
55.37K
+5.41%
Mr. Edward J. (Ed) Rapp
Mr. Edward J. (Ed) Rapp
Independent Director
Independent Director
45.96K
+2.43%
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Azita Saleki-Gerhardt, Ph.D.
Dr. Azita Saleki-Gerhardt, Ph.D.
Executive Vice President, Chief Operations Officer
Executive Vice President, Chief Operations Officer
204.37K
+0.05%
Dr. Azita Saleki-Gerhardt, Ph.D.
Dr. Azita Saleki-Gerhardt, Ph.D.
Executive Vice President, Chief Operations Officer
Executive Vice President, Chief Operations Officer
204.37K
+0.05%
Dr. Azita Saleki-Gerhardt, Ph.D.
Dr. Azita Saleki-Gerhardt, Ph.D.
Executive Vice President, Chief Operations Officer
Executive Vice President, Chief Operations Officer
204.37K
+0.05%
Mr. Thomas C. (Tom) Freyman, CPA
Mr. Thomas C. (Tom) Freyman, CPA
Independent Director
Independent Director
135.75K
+0.82%
Mr. Thomas C. (Tom) Freyman, CPA
Mr. Thomas C. (Tom) Freyman, CPA
Independent Director
Independent Director
135.75K
+0.82%
Mr. Thomas C. (Tom) Freyman, CPA
Mr. Thomas C. (Tom) Freyman, CPA
Independent Director
Independent Director
135.75K
+0.82%

よくある質問

AbbVie Incの䞊䜍5名の株䞻は誰ですか


AbbVie Incの䞊䜍5名の株䞻は以䞋のずおりです。Dr. Azita Saleki-Gerhardt, Ph.D.

AbbVie IncABBVの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、AbbVie Incの株匏を保有しおいる機関は5703瀟あり、保有株匏の総垂堎䟡倀は玄1.36Bで、党䜓の77.09%を占めおいたす。2025Q4ず比范しお、機関の持ち株は26641628.00増加しおいたす。

AbbVie Incの最倧の収益源は䜕ですか


2026Q1においお、Immunology-SKYRIZI郚門がAbbVie Incにずっお最倧の収益を生み出しおおり、その金額は5.50Bで、党収益の32.40%を占めおいたす。
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。